ACON Overview

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aclarion Inc revenue for the last quarter amounts to 21.14K USD, increased 11.32

Aclarion Inc. EPS for the last quarter amounts to -1.34 USD, decreased -85.62

Aclarion Inc (ACON) has 11 emplpoyees as of June 20 2026.

Today ACON has the market capitalization of 7.68M USD.